tbuckley/cabot-search huggingface dataset:
Abstract 4136632: Impact of Postoperative Atrial Fibrillation on Long-term Clinical Outcomes in Patients after Coronary Artery Bypass Grafting
Authors: Yuki Kuroda, Hiroki Shiomi, Takeshi Morimoto, Shingo Hirao, Hideki Tsubota, Takehiko Matsuo, Kyokun Uehara, Jiro Esaki, Takeshi Shimamoto, Hideo Kanemitsu, Hiroshi Tsuneyoshi, Naoki Kanemitsu, Atsushi Iwakura, Nobushige Tamura, Yutaka Furukawa, Kazushige Kadota, Kenji Ando, Nobuhisa Ohno, Tatsuhiko Komiya, Takeshi Kimura, Kenji Minatoya
Journal: Circulation (2024)

Background: The impact of postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) on long-term clinical outcomes has not been adequately evaluated yet. Methods: Among consecutive 14927 patients who underwent their first coronary revascularization in the CREDO-Kyoto PCI/CABG Registry Cohort-3 (2011-2013), the study population consisted of 1483 patients who underwent CABG after excluding those with prior AF. POAF was defined as newly documented AF during hospitalization for CABG. The primary outcome measure was all-cause death after discharge. The median clinical follow-up was 5.7 (interquartile range, 4.4-6.6) years. Results: POAF was observed in 337 patients (23%). Multivariable logistic regression analysis indicated that age &gt;=75 years (odds ratio [OR], 1.61; 95% confidence interval [CI], 1.24-2.10; P&lt;0.001) and cardiopulmonary bypass (CPB) use (OR, 1.40; 95%CI, 1.09-1.79; P=0.01) were independent predictors of POAF. Of the 1400 patients discharged alive among the study population, the POAF group included more older patients, patients with prior stroke, and patients prescribed beta-blockers and oral anticoagulants than the non-POAF group. The cumulative 5-year incidence of all-cause death was 15.9% in the POAF group and 13.0% in the non-POAF group (Log-rank P=0.38). After adjusting for confounders, the adjusted risk for all-cause death was almost neutral (adjusted HR, 0.96; 95%CI, 0.70-1.31; P=0.81). The cumulative 5-year incidence of stroke was significantly higher in the POAF group than in the non-POAF group (8.0% versus 4.2%; Log-rank P=0.02), and the adjusted risk of stroke in the POAF group relative to the non-POAF group tended to be higher (adjusted HR: 1.58, 95%CI, 0.99-2.53; P=0.057). However, the cumulative 5-year incidence of major bleeding was significantly higher in the POAF group than in the non-POAF group (14.6% versus 10.7%; Log-rank P=0.01). Even after adjusting for confounders, the excess risk of major bleeding in the POAF group was significant (adjusted HR, 1.42; 95%CI, 1.01-2.00; P=0.041). Conclusions: Advanced age and CPB use were associated with POAF occurrence. POAF was not associated with long-term mortality after discharge. However, it tended to be associated with a higher risk for stroke and was associated with a significantly higher risk for major bleeding. Further study would be needed to clarify the appropriate management of POAF after CABG.
Abstract 4136273: A Machine Learning Approach to Simplify Risk Stratification of Patients with Atherosclerotic Cardiovascular Disease
Authors: Hsin Fang Li, Andrew Nute, Roshanthi Weerasinghe, Staci Wendt, Eleni Wilson, Eduard Sidelnikov, Niranjan Kathe, Charissa Swihart, Laney Jones, Ty Gluckman
Journal: Circulation (2024)

Introduction: The 2018 AHA/ACC/Multisociety Blood Cholesterol Guideline recommends that patients with atherosclerotic cardiovascular disease (ASCVD) be classified as very high-risk (VHR) or not very high-risk (NVHR). This designation is based on the presence of &gt; 2 major ASCVD events (recent acute coronary syndrome [ACS], history of myocardial infarction [MI], history of ischemic stroke, symptomatic peripheral artery disease [PAD]) or 1 major ASCVD event and &gt; 2 high-risk conditions (age ≥65 years, heterozygous familial hypercholesterolemia, history of coronary revascularization, diabetes, hypertension, chronic kidney disease, current smoking, persistently elevated LDL-cholesterol [LDL-C], history of heart failure). While this approach was initially instituted to better predict future ASCVD events alone, more intensive LDL-C lowering is now recommended for those at VHR (LDL-C treatment threshold of 55 mg/dL for VHR patients vs 70 mg/dL for NVHR patients). We aimed to simplify ASCVD risk stratification in patients with clinical ASCVD using machine learning models. Methods: We used electronic health record data (Providence Health system) from 2022 to identify patients with ASCVD based on ICD-10 codes. Patient demographics, comorbidities, and laboratory data stratified patients as VHR or NVHR. Then, a classification and regression tree analysis was performed, with the outcome being VHR classification. Patients were randomly assigned to either the testing or training dataset in equal proportion. Variables in the model included age, sex, race, ethnicity, and the Guideline criteria. Model performance was assessed using misclassification rate and area under the receiver operative curve (AUC). Results: A total of 491,514 patients with ASCVD were included, of which 56% were male, 77% were white, and the mean (SD) age was 72.5 (13.0) years. Over half of patients (59%) were VHR. Those with recent ACS, history of MI, history of ischemic stroke, or PAD were classified as VHR 93%, 92%, 84%, and 91%, respectively. Presence of hypertension in these patients increased the likelihood of being VHR to 97%, 97%, 94%, and 98%, respectively. The misclassification rate and AUC for the testing set were 6.8% and 96.2%, respectively. Conclusions: Most patients with a major ASCVD event and hypertension were found to be VHR. Relying on these two factors alone can help simplify risk assessment. This approach may also help increase use of guideline-recommended LDL-C lowering therapy.
Abstract 4136009: Adherence and Persistence to Guideline-Directed Medical Therapy in Patients with Heart Failure: A Systematic Review and Meta-Analysis
Authors: Jungyeon Moon, Erin Chiang, Albert Rodriguez, Aya Ozaki, Douglas Lee, Freny Mody, Jacob Udell, Cynthia Jackevicius
Journal: Circulation (2024)

Introduction: Since individual adherence/persistence studies for heart failure (HF) guideline-directed medical therapy (GDMT) have mainly focused on single classes or had limited sample sizes, providing inconclusive estimates, a comprehensive analysis is needed to understand the magnitude of the problem. Hypothesis: Adherence and persistence to HF GDMT are suboptimal and are associated with increased risks of HF admission and mortality. Aims: To generate estimates of real-world HF medication adherence and persistence and associated clinical outcomes. Methods: We conducted a systematic review and meta-analysis, searching PubMed, EMBASE, and CINAHL for observational studies on adherence and persistence in HF GDMT from inception to 9/25/23. We evaluated bias using the Newcastle-Ottawa Scale. Primary outcomes were adherence and persistence rates using a restricted maximum-likelihood model. Adherence was summarized as the mean proportion of days covered (PDC) and medication possession ratio (MPR), proportion of patients with good adherence (PDC/MPR≥80%), and persistence. Secondary outcomes were all-cause mortality and HF readmission with summary hazard ratios (HRs) and 95% confidence intervals (CI) estimated. Heterogeneity and publication bias were assessed using Cochran’s Q, I squared statistics, funnel plots, and Egger's tests, while subgroup analyses explored variations across studies. Results: The 48 studies included comprised 1,614,985 patients (mean age 71; 57% men). The overall mean PDC/MPR was 76%, with good adherence of 54%, and persistence rates of 60%. Renin-angiotensin-aldosterone system inhibitors had the highest mean PDC/MPR of 78%, good adherence of 56%, and persistence of 64%, while mineralocorticoid receptor antagonists (MRAs) had the lowest at 71%, 47%, and 49% respectively. Nonadherence/nonpersistence to GDMT was associated with a higher rate of mortality (HR 1.27 [95% CI 1.19–1.35]) and HF admission (HR 1.25 [95% CI 1.14-1.37]). Conclusions: Suboptimal adherence/persistence to HF GDMT is common, with only half of patients showing good adherence. Given the association with worse clinical outcomes, clinicians should prioritize identifying barriers to and addressing nonadherence/nonpersistence to HF GDMT, particularly with MRAs.
Abstract 4136316: BMP10 as novel marker for right atrial dilatation and pressure in precapillary pulmonary hypertension
Authors: Aida Llucia-Valldeperas, Jessie Van Wezenbeek, Joanne Groeneveldt, Gonzalo Sanchez-Duffhues, Anton Vonk Noordegraaf, Harm Bogaard, Marie Jose Goumans, Frances De Man
Journal: Circulation (2024)

Introduction: Precapillary pulmonary hypertension (precPH) leads to increased right atrial (RA) stretch and pressure. The right atrium is the major source of bone morphogenetic protein 10 (BMP10) in adults. Aim: This study aims to investigate BMP10 in relation to RA dilatation and pressure overload. Methods: We studied BMP10 mRNA in fresh RA tissue of N=5 Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients and N=9 controls and protein expression in paraffin-embedded RA tissue of N=4 Pulmonary Arterial Hypertension (PAH) patients and N=6 controls. We prospectively included 48 precPH patients (N=22 idiopathic PAH, N=14 hereditary PAH and N=12 CTEPH, and N=16 controls. To study BMP10-induced transcriptional activity, we assayed serum samples in human microvascular endothelial cells (HMEC) with a BMP-responsive transcriptional luciferase assay. BMP10 activity was calculated by subtracting BMP activity after incubation with antibodies for Alk1Fc and bone morphogenetic protein 9 (BMP9). We assessed correlations between BMP10 activity and RA dilatation (RA max volume&gt;79 ml/m 2 for male or &gt;69 ml/m 2 for female) and right ventricular (RV) dilatation (RV end-diastolic volume&gt;108 ml/m 2 for male and &gt;96 ml/m 2 for female). In a cohort of CTEPH patients that underwent pulmonary endarterectomy (PEA) we assessed the effect of pressure unloading on BMP10 activity. Normality of data was checked and statistical differences between groups were tested using an independent sample t-test or Wilcoxon rank-sum test. Results: BMP10 mRNA, protein and downstream activity were higher in the precPH RA tissue (Figure 1A-F). High systemic BMP10 activity was associated with RA dilatation and high RA pressure, but not RV dilatation in precPH (Figure 2A-C). Finally, pressure unloading after PEA in CTEPH patients results in a reduction in BMP10 activity (figure 2D). Conclusions: Local RA BMP10 expression and activity is increased in precPH. Increased systemic BMP10 activity was related to RA dilatation and pressure. Pressure unloading of the right heart leads to a reduction of systemic BMP10 activity. Future studies are needed to determine whether increased BMP10 release is an adaptative mechanism or can be used as therapeutic target.
Abstract 4136480: A Rare Cause of a Classic Presentation of NSTEMI: Case of 39-Year-Old Female with Hypothyroidism Induced Myocarditis
Authors: Fayz Quadri, Mariam Qazi, Taylor Teague
Journal: Circulation (2024)

Background: Myocarditis is a cause of non-ischemic cardiomyopathy (NICM) and troponin elevation. There are many causes including uncontrolled thyroid disorder (TD). A thorough history, cardiac MRI (cMRI) followed by an endomyocardial biopsy (EMB) is necessary for diagnosis. This case illustrates a classic presentation of NSTEMI with a rare cause of myocarditis due to uncontrolled hypothyroidism. Description of Case: A 39-year-old female with history of congenital hypothyroidism and tobacco use disorder presented to the Emergency Department with sudden onset of unprovoked sub-sternal chest pain. She stated she had stopped taking her levothyroxine years ago due to side effects such as abdominal discomfort. On admission, work up included high sensitivity troponin (Hs-cTn), EKG, urine drug screen (UDS), and thyroid panel. There was no evidence of ischemic changes on EKG, Hs-cTn was 3600 (normal: 3-54) which up-trended to 43,742, and UDS was negative. She was placed on appropriate medical therapy for NSTEMI and taken for urgent coronary angiography wbich showed normal epicardial arteries. A transthoracic echocardiogram (TTE) was unremarkable with a normal ejection fraction (EF). However, she continued to complain of chest discomfort and palpitations. Her vital signs remained stable but her thyroid panel revealed a TSH of 127 (normal: 0.27-4.2), T4 of 0.18 (normal: 0.92 – 1.6) and T3 of 1.0 (normal: 2.3-4.2). Inflammatory markers were also elevated. A cMRI was obtained revealing gadolinium enhancement in the anterior septal wall with extension into the subepicardium of the inferior wall suggestive of possible myocarditis. An EMB was performed to elucidate etiology. Pathology results were only remarkable for edema but newly reduced EF of 30-35% was noted on TTE at time of biopsy. Endocrinology was consulted for untreated hypothyroidism and patient was initiated on levothyroxine leading to improvement of her symptoms. Discussion: Our patient's history and work up were consistent with myocarditis induced by severe hypothyroidism. TD is a rare cause of reversible NICM and symptoms improve once TD is controlled. While there are several cases reported on hyperthyroidism associated myocarditis, there are only a few cases of myocarditis associated with uncontrolled hypothyroidism. Clinicians should maintain a broad differential to ensure a thorough work up in a patient presenting with NSTEMI, and a thyroid panel should be included especially if myocarditis is suspected.
Abstract 4136592: Comparative performance of PREVENT and Pooled Cohort Equations to predict cardiovascular disease in multisite healthcare populations
Authors: So Mi Cho, Michael Levin, Robert Chen, Renae Judy, Darina Postupaka, Victoria Viscosi, Akl Fahed, Michael Honigberg, Whitney Hornsby, Scott Damrauer, Ron Do, Pradeep Natarajan
Journal: Circulation (2024)

Introduction: The American Heart Association’s race-agnostic Predicting Risk of cardiovascular EVENTs (PREVENT) framework has emerged to better capture multilevel determinants of health in contemporary population. Whether PREVENT better predicts incident atherosclerotic cardiovascular disease (ASCVD) than the preceding Pooled Cohort Equations (PCE) is unknown in healthcare populations. We evaluated calibration and discrimination of the two equations across three major U.S. healthcare networks. Methods: We retrospectively evaluated electronic health records of 209,879 individuals (Mass General Brigham [MGB]: 118,801; Mount Sinai Healthcare System: 38,834; Penn Medicine: 52,424) aged 40-79 years and without prior ASCVD between 2010-2012. Calibration was assessed using discordance ratio between 10-year observed and predicted risk. Discrimination was evaluated by Harrell’s C-index. Results: Based on PREVENT, the mean [SD] estimated 10-year ASCVD risk ranged from 5.5 [4.7] % in MGB (mean age 56y, 42% female), 6.6 [5.6]% in Mount Sinai (59y, 54% female), and 6.4 [5.2]% in Penn (60y, 55% female). PREVENT substantially underestimated empirical 10-year ASCVD incidence in MGB (16.9%) and Mount Sinai (10.9%), whereas it closely mirrored the observed rate in Penn (5.5%). Both PCE and PREVENT had comparable discrimination C-index [95% CI] across MGB (0.69 [0.69-0.70] vs. 0.69 [0.68-0.69]), Mount Sinai (0.72 [0.71-0.73] vs. 0.70 [0.70-0.71]), and Penn (0.68 [0.67-0.69] vs. 0.67 [0.66-0.68]). Nevertheless, compared to PREVENT, PCE demonstrated better overall calibration in MGB (-70% vs. -42%) and Mount Sinai (-36% vs. +5%), whereas largely overestimated risk in Penn (+3% vs +94%). Calibration varied across demographics with PREVENT consistently underestimating risk in Hispanics, Asians, Black and African Americans across all sites, whereas PCE largely overestimated risk for White or multiracial Penn healthcare patients. Conclusions: The race-agnostic PREVENT model discriminated ASCVD incidence comparably or better than the race-informed PCE across three geographically distinct academic health systems in the Northeast. However, calibration metrics between the two models varied widely across health systems and demographics.
Abstract 4136136: Left Ventricular Global Longitudinal Strain: An Imaging Marker Associated with Improved Survival in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis
Authors: Shani Dahan, Nathanael Tran, Jagdip Kang, Jacob Dal-Bianco, Judy Hung
Journal: Circulation (2024)

Background: The optimal clinical management and timing of intervention are less well defined in paradoxical low-flow, low-gradient severe aortic stenosis (PLFLG AS). Left ventricular global longitudinal strain (LV-GLS) has been shown to predict outcomes in high flow severe AS, but there is lack of data in patients with PLFLG AS. Given the exaggerated LV hypertrophy and remodeling pattern in PLFLG AS, LV-GLS may be a mechanistic imaging marker for worse outcomes. Hypothesis: In patients with PLFLG AS, LV-GLS is associated with adverse clinical outcomes by detecting subclinical myocardial fibrosis resulting from myocardial remodeling due to LV pressure overload. Methods: We examined patients with PLFLG AS defined as AVA &lt;1cm 2 , mean gradient &lt;40mmHg and preserved left ventricular ejection fraction (LVEF) ≥50%, with low-flow state defined as transvalvular flow rate (Q) ≤210 ml/sec. Exclusion criteria included moderate or greater mitral or aortic regurgitation and presence of atrial fibrillation at the time of echocardiogram. LV strain analysis was performed using 2D-strain imaging software (TomTec, Chicago, IL). Clinical outcome data were obtained via the electronic health record. The primary outcome was defined as all-cause mortality. Patients were stratified by LV-GLS above and below the median value. Results: A total of 198 patients were included in the analysis, with a median LV-GLS of -12.3% [IQR: (-9.8,-16.3)]. Over a median follow-up time of 1.2 years, 130 deaths (65.6%) were identified. Patients with less negative LV-GLS (n=101) had worse survival than those with more negative LV-GLS (n=97; 22 vs 38%; p=0.02) (Fig 1). After multivariable adjustment for potential confounders (stroke volume index, aortic valve mean gradient, relative wall thickness, age, sex, heart failure, hypertension, coronary artery disease, and diabetes), less negative LV-GLS was independently associated with adverse outcomes (HR 1.56; 95% CI (1.03-2.38); p=0.04). Conclusions: In patients with PLFLG AS as defined by a transvalvular flow rate (Q) ≤210 ml/sec, reduced LV-GLS is associated with increased all-cause mortality. LV-GLS may serve as an imaging marker to help guide clinical decision making in PLFLG AS.
Abstract 4135333: Peripheral Perfusion Index: Normative Values From Electronically Reported Critical Congenital Heart Disease Screenin
Authors: Tobias Donlon, Jamie Lohr, Scott Lunos, Katie Pfister, Amanda Pavan, Melissa Engel
Journal: Circulation (2024)

Background: Critical Congenital Heart Disease (CCHD) screening is performed in an effort to reduce morbidity and mortality associated with CCHD by facilitating early detection. This screening consists of pulse oximetry and is most effective at identification of cyanotic cardiac lesions, with less sensitivity for left sided obstructive lesions. Research: Question Peripheral perfusion index (PPI) is obtained from the plethysmographic signal of a pulse oximeter and represents the ratio of pulsatile to non-pulsatile blood flow. As such, it is a surrogate for peripheral perfusion at the site of measurement. PPI has been postulated to be an adjunctive screening method for low perfusion states in neonates, including left sided obstructive lesions. To date, reference ranges of PPI values in neonates have not been published in the United States. This project utilized electronically reported CCHD screening results to establish normative PPI data in healthy neonates. Methods: In Minnesota, CCHD screening results are electronically sent to the Minnesota Department of Health (MDH) and are cross referenced against the Minnesota Birth Information System, which tracks infants who are identified to have a congenital birth defect within the first year of life. These data were provided by the MDH for infants born in Minnesota from Jan 2017 through Dec 2022. Infants were included in the analysis if they did not have a known critical congenital heart defect, were born between 35 and 42 weeks gestation, and were 24-48 hours of life at time of screening. Results: PPI data from 11,179 cases were included in the analysis. Overall, there is a trend towards increasing PPI with gestational age. Pre-ductal PPI trended higher than post-ductal PPI. There was no difference between PPI in males and females. Conclusions: These data reflect trends identified in international data. This is the largest dataset to date of PPI in healthy neonates and the first in the United States. Future studies will compare neonates with left sided obstructive lesions against these normative data. If PPI is found to predict left sided obstructive lesions in neonates, there may be utility in use of PPI in CCHD screening to facilitate earlier detection of these lesions.
Abstract 4135517: Echocardiographic Biomarkers Enhance Mortality Predictions in Cirrhosis Patients
Authors: Brett Meyers, Yannis Dimitroglou, Constantina Aggeli, Pavlos Vlachos
Journal: Circulation (2024)

Introduction: Cirrhosis, a late-stage liver disease, is associated with numerous systemic complications, making long-term mortality prediction challenging. Traditional models like Child-Pugh and MELD are primarily designed for short-term (3-month) mortality. This study evaluates the impact of incorporating echocardiographic (echo) variables in predicting long-term mortality in cirrhosis patients. Methods: A retrospective cohort study was conducted using data from 60 patients with clinically diagnosed cirrhosis from Hippokration Hospital, Greece, spanning 2018 to 2022. Patients were followed for up to 52 months. Exclusion criteria included pre-existing cardiovascular diseases and significant co-morbidities. Patients were categorized into survived to end of study (n=31) and died during study (n=29) groups. Outcomes were analyzed using multivariate logistic regression and Cox proportional hazards models, and include parameters for age, blood pressure, lab-based biomarkers (potassium, pro-brain natriuretic peptide, hemoglobin, platelet count, aspartate transaminase, gamma-glutamyl transferase, uric acid), and echo/ecg measurements (QT interval, left ventricular (LV) ejection fraction, LV global longitudinal strain (GLS), left atrial GLS, annulus velocities, and E/A ratio). Results: The multivariate logistic regression model (MELD+) that included echo variables showed a 10% improvement in area under the curve (AUC: 0.901) compared to the MELD model alone (AUC: 0.817). MELD+ improved risk classification accuracy by nearly 10% with a conservative threshold. The Cox proportional hazards model with MELD+ also demonstrated superior performance (AUC: 0.923; C-index: 0.875; Brier Score: 0.097) compared to the MELD model alone (AUC: 0.892; C-index: 0.831; Brier Score: 0.134). The MELD+ model showed less variation in hazard ratio confidence intervals, indicating more consistent risk estimation. Conclusion: Incorporating echocardiographic measurements enhances the accuracy of long-term mortality predictions in cirrhosis patients. These findings suggest that cardiac imaging should be considered in risk assessments for cirrhosis patients, particularly for predicting survival beyond three months.